샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533797

심막염 치료제 시장

Pericarditis Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 289 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 심막염 치료제 시장은 2030년까지 47억 달러에 이를 전망

2023년에 37억 달러로 평가된 세계의 심막염 치료제 시장은 2023년부터 2030년까지 CAGR 3.5%로 성장할 전망이며, 2030년에는 47억 달러에 이를 것으로 예측됩니다. 비스테로이드성 항염증제(NSAIDs)는 본 보고서에서 분석한 부문 중 하나이며 CAGR 3.7%로 성장을 지속하고, 분석 기간 종료 시 25억 달러에 달할 것으로 예측됩니다. 콜히친 약물 부문은 분석 기간 동안 CAGR 2.8%에서 성장할 것으로 추정됩니다.

미국 시장은 10억 달러로 추정, 중국은 CAGR 6.7%로 성장 예측

미국의 심막염 치료제 시장은 2023년 10억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 분석 기간 2023년부터 2030년까지 CAGR 6.7%로 전망되며, 2030년까지 예측 시장 규모 9억 6,900만 달러에 달할 것으로 예측됩니다. 다른 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.1%와 2.6%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.

심막염 치료제-주요 동향 및 촉진요인

심막염 치료제 시장은 심혈관 질환 증가에 의해 현저한 시장 개척을 볼 수 있습니다. 심혈관 질환은 여전히 세계의 사망 원인의 1위이며, 관상동맥성 심장 질환이나 뇌혈관 질환과 같은 질환이 연간 약 1,790만 명의 생명을 빼앗고 있습니다. 심막염은 심장 수술과 심장 발작 후에 발병하는 경우가 많으며, 심혈관 질환의 발생률이 높아지면 심막염 치료에 대한 수요 증가에 직결하고 있습니다. 심막염의 재발, 특히 환자의 30% 가까이를 앓고 있는 초기 발병 후 재발은 이러한 수요를 더욱 증폭시킵니다. KPL-914 및 Dexamethasone과 같은 더 효과적이고 안전한 치료 방법을 탐구하는 약물에 중점을 둔 여러 임상시험에서 볼 수 있듯이 심막염에 대한 새로운 치료법의 지속적인 연구 개발은 매우 중요합니다.

이러한 요구가 높아짐에 따라 심막염 치료제 시장에서는 약물 개발 및 치료법 개선에 큰 동향을 볼 수 있습니다. 예를 들어, 비스테로이드성 항염증제(NSAIDs) 부문은 심막염 환자의 주소인 흉통과 같은 증상을 완화시키는 효과가 있기 때문에 시장을 석권할 것으로 예상됩니다. 약물 요법의 진보도 주목받고 있으며, NLRP3 인프라마좀/IL-1축을 표적으로 하는 신약이 재발례에 대해 유망시되고 있습니다. 이 시장에서 북미가 지리적으로 우위를 차지하고 있는 것은 심장 질환의 유병률이 높고 헬스 케어의 연구 개발이 충실해 심장 관련의 염증에 대한 환자의 의식이 높아지고 있기 때문입니다. 그러나 약물의 부작용과 고도의 치료와 관련된 높은 비용과 같은 문제는 시장 성장을 억제할 수 있습니다. 그럼에도 불구하고 진행 중인 임상시험과 세계의 의료 인프라에 대한 투자 증가가 시장을 견인하여 심막염 치료에서 광범위한 성장과 개척을 보장할 것으로 기대되고 있습니다.

조사 대상 기업 예(주목의 52사)

  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiol Therapeutics Inc.
  • Dr. Reddy's Laboratories Ltd
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Kiniksa Pharmaceuticals Corp.
  • Lupin Pharmaceutical, Inc.
  • Novartis International AG
  • Takeda Pharmaceutical Co. Ltd
  • Teva Pharmaceutical Industries Ltd(Israel)
  • Viatris Inc.;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.08.22

Global Pericarditis Drugs Market to Reach US$4.7 Billion by 2030

The global market for Pericarditis Drugs estimated at US$3.7 Billion in the year 2023, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Colchicine Drugs segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 6.7% CAGR

The Pericarditis Drugs market in the U.S. is estimated at US$1.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$969.0 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Pericarditis Drugs - Key Trends and Drivers

The pericarditis drugs market has seen notable developments, driven by the increase in cardiovascular diseases. Cardiovascular conditions remain the leading cause of global mortality, with conditions like coronary heart disease and cerebrovascular disease claiming about 17.9 million lives annually. Pericarditis often follows cardiac surgeries and heart attacks, linking the high incidence of cardiovascular conditions directly to increased demand for pericarditis treatments. The recurrence of pericarditis, particularly after the first episode, which affects nearly 30% of patients, further amplifies this demand. As such, ongoing research and development in new therapies for pericarditis are crucial, as seen in several clinical trials focusing on drugs like KPL-914 and Dexamethasone, which are exploring more effective and safer treatment avenues.

In response to the burgeoning need, the pericarditis drugs market is witnessing significant trends in drug development and therapy improvements. The NSAIDs segment, for example, is expected to dominate the market due to its effectiveness in reducing symptoms such as chest pain, a primary complaint of pericarditis patients. Advancements in pharmacotherapy are also being noted, with newer drugs targeting the NLRP3 inflammasome/IL-1 axis showing promise for recurrent cases. The geographical dominance of North America in this market is attributed to high cardiac disease prevalence, substantial healthcare R&D, and heightened patient awareness regarding heart-related inflammations. However, challenges such as the side effects of drugs and the high costs associated with advanced therapies could restrain market growth. Nonetheless, the ongoing clinical trials and increasing investments in health infrastructure globally are expected to drive forward the market, ensuring extensive growth and development in the treatment of pericarditis.

Select Competitors (Total 52 Featured) -

  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiol Therapeutics Inc.
  • Dr. Reddy's Laboratories Ltd
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Kiniksa Pharmaceuticals Corp.
  • Lupin Pharmaceutical, Inc.
  • Novartis International AG
  • Takeda Pharmaceutical Co. Ltd
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Viatris Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Pericarditis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Cardiac Disorders Driving Demand for Pericarditis Treatment
    • Advances in Targeted Therapy for Autoimmune-Related Pericarditis
    • Development of Novel Anti-inflammatory Drugs
    • Patient Awareness and Growing Demand for Early Treatment
    • Challenges in Diagnosis and Treatment of Recurrent Pericarditis
    • Regulatory Support for Fast-Tracking Critical Cardiovascular Drugs
    • Adoption of Combination Therapies for Enhanced Treatment Outcomes
    • Research Funding for Cardiovascular Diseases Influencing Market Dynamics
    • Technological Advances in Diagnostic Methods for Early Detection
    • Patent Expiries and the Surge of Generics in the Market
    • Strategic Alliances Among Biopharmaceuticals for Drug Development
    • Global Initiatives to Reduce Burden of Cardiovascular Diseases
    • Impact of Lifestyle Changes on Incidence and Management of Pericarditis
    • Integration of Pharmacogenomics in Personalized Medication
    • Growing Role of AI in Clinical Trials and Drug Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pericarditis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pericarditis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pericarditis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pericarditis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colchicine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Colchicine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Colchicine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pericarditis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pericarditis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Pericarditis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pericarditis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pericarditis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Pericarditis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pericarditis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pericarditis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Pericarditis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pericarditis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pericarditis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Pericarditis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Pericarditis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pericarditis Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Pericarditis Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Pericarditis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Pericarditis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제